Search

Your search keyword '"Yutani, Shigeru"' showing total 180 results
Start Over Author "Yutani, Shigeru"
180 results on '"Yutani, Shigeru"'

3. Data from Phase II Study of Personalized Peptide Vaccination for Previously Treated Advanced Colorectal Cancer

Author

Kibe, Shiro, primary, Yutani, Shigeru, primary, Motoyama, Satoru, primary, Nomura, Takanobu, primary, Tanaka, Natsuki, primary, Kawahara, Akihiko, primary, Yamaguchi, Tomohiko, primary, Matsueda, Satoko, primary, Komatsu, Nobukazu, primary, Miura, Masatomo, primary, Hinai, Yudai, primary, Hattori, Satoshi, primary, Yamada, Akira, primary, Kage, Masayoshi, primary, Itoh, Kyogo, primary, Akagi, Yoshito, primary, and Sasada, Tetsuro, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Methods from Phase II Study of Personalized Peptide Vaccination for Previously Treated Advanced Colorectal Cancer

Author

Kibe, Shiro, primary, Yutani, Shigeru, primary, Motoyama, Satoru, primary, Nomura, Takanobu, primary, Tanaka, Natsuki, primary, Kawahara, Akihiko, primary, Yamaguchi, Tomohiko, primary, Matsueda, Satoko, primary, Komatsu, Nobukazu, primary, Miura, Masatomo, primary, Hinai, Yudai, primary, Hattori, Satoshi, primary, Yamada, Akira, primary, Kage, Masayoshi, primary, Itoh, Kyogo, primary, Akagi, Yoshito, primary, and Sasada, Tetsuro, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Table S5 from Phase II Study of Personalized Peptide Vaccination for Previously Treated Advanced Colorectal Cancer

Author

Kibe, Shiro, primary, Yutani, Shigeru, primary, Motoyama, Satoru, primary, Nomura, Takanobu, primary, Tanaka, Natsuki, primary, Kawahara, Akihiko, primary, Yamaguchi, Tomohiko, primary, Matsueda, Satoko, primary, Komatsu, Nobukazu, primary, Miura, Masatomo, primary, Hinai, Yudai, primary, Hattori, Satoshi, primary, Yamada, Akira, primary, Kage, Masayoshi, primary, Itoh, Kyogo, primary, Akagi, Yoshito, primary, and Sasada, Tetsuro, primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure S2 from Phase II Study of Personalized Peptide Vaccination for Previously Treated Advanced Colorectal Cancer

Author

Kibe, Shiro, primary, Yutani, Shigeru, primary, Motoyama, Satoru, primary, Nomura, Takanobu, primary, Tanaka, Natsuki, primary, Kawahara, Akihiko, primary, Yamaguchi, Tomohiko, primary, Matsueda, Satoko, primary, Komatsu, Nobukazu, primary, Miura, Masatomo, primary, Hinai, Yudai, primary, Hattori, Satoshi, primary, Yamada, Akira, primary, Kage, Masayoshi, primary, Itoh, Kyogo, primary, Akagi, Yoshito, primary, and Sasada, Tetsuro, primary

Published
2023
Full Text
View/download PDF

16. Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: A new biomarker for overall survival of patients with malignant diseases

Author

Matsueda, Satoko, Komatsu, Nobukazu, Kusumoto, Kenichi, Koga, Shintaro, Yamada, Akira, Kuromatsu, Ryoko, Yamada, Shingo, Seki, Ritsuko, Yutani, Shigeru, Shichijo, Shigeki, Mine, Takashi, Fukuda, Takaaki, Okamura, Takashi, Okuda, Seiya, Sata, Michio, Honda, Junichi, Kaji, Masahide, Itoh, Kyogo, and Sasada, Tetsuro

Published
2013
Full Text
View/download PDF

19. Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients

Author

Suekane, Shigetaka, primary, Yutani, Shigeru, additional, Yamada, Akira, additional, Sasada, Tetsuro, additional, Matsueda, Satoko, additional, Takamori, Shinzo, additional, Toh, Uhi, additional, Kawano, Kouichiro, additional, Yoshiyama, Koichi, additional, Sakamoto, Shinjiro, additional, Sugawara, Shunichi, additional, Komatsu, Nobukazu, additional, Yamada, Teppei, additional, Naito, Masayasu, additional, Terasaki, Mizuhiko, additional, Mine, Takashi, additional, Itoh, Kyogo, additional, Shichijo, Shigeki, additional, and Noguchi, Masanori, additional

Published
2020
Full Text
View/download PDF

30. A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer

Author

Shirahama, Takahisa, primary, Muroya, Daisuke, additional, Matsueda, Satoko, additional, Yamada, Akira, additional, Shichijo, Shigeki, additional, Naito, Masayasu, additional, Yamashita, Takuto, additional, Sakamoto, Shinjiro, additional, Okuda, Koji, additional, Itoh, Kyogo, additional, Sasada, Tetsuro, additional, and Yutani, Shigeru, additional

Published
2017
Full Text
View/download PDF

31. Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ allele

Author

Sakamoto, Shinjiro, primary, Matsueda, Satoko, additional, Takamori, Shinzo, additional, Toh, Uhi, additional, Noguchi, Masanori, additional, Yutani, Shigeru, additional, Yamada, Akira, additional, Shichijo, Shigeki, additional, Yamada, Teppei, additional, Suekane, Shigetaka, additional, Kawano, Kouichiro, additional, Naitou, Masayasu, additional, Sasada, Tetsuro, additional, Hattori, Noboru, additional, Kohno, Nobuoki, additional, and Itoh, Kyogo, additional

Published
2017
Full Text
View/download PDF

32. MP78-06 PHASE II STUDY OF PERSONALIZED PEPTIDE VACCINATION FOR METASTATIC UPPER TRACT UROTHELIAL CANCER PATIENTS REFRACTORY TO THE STANDARD CHEMOTHERAPY

Author

Suekane, Shigetaka, primary, Ueda, Kousuke, additional, Nishihara, Kiyoaki, additional, Igawa, Tsukasa, additional, Noguchi, Masanori, additional, Sasada, Tetsuro, additional, Yamashita, Takuto, additional, Yutani, Shigeru, additional, Shichijo, Shigeki, additional, and Itoh, Kyogo, additional

Published
2017
Full Text
View/download PDF

33. Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer

Author

Muroya, Daisuke, primary, Yutani, Shigeru, additional, Shichijo, Shigeki, additional, Yamada, Akira, additional, Sakamoto, Shinjiro, additional, Naito, Masayasu, additional, Okuda, Koji, additional, Morita, Michi, additional, Yamaguchi, Rin, additional, and Itoh, Kyogo, additional

Published
2016
Full Text
View/download PDF

34. Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination

Author

Sakamoto, Shinjiro, Yoshitomi, Munehiro, Yutani, Shigeru, Terazaki, Yasuhiro, Yoshiyama, Koichi, Ioji, Tetsuya, Matsueda, Satoko, Yamada, Akira, Takamori, Shinzo, Itoh, Kyogo, Hattori, Noboru, Kohno, Nobuoki, Sasada, Tetsuro, Sakamoto, Shinjiro, Yoshitomi, Munehiro, Yutani, Shigeru, Terazaki, Yasuhiro, Yoshiyama, Koichi, Ioji, Tetsuya, Matsueda, Satoko, Yamada, Akira, Takamori, Shinzo, Itoh, Kyogo, Hattori, Noboru, Kohno, Nobuoki, and Sasada, Tetsuro

Abstract

Since cancer vaccines do not always elicit beneficial effects in treated patients, identification of biomarkers for predicting clinical outcomes would be highly desirable. We previously reported that abnormal granulocytes present in peripheral blood mononuclear cells (PBMC) may contribute to poor prognosis in advanced prostate cancer patients receiving personalized peptide vaccination (PPV). In the current study, we examined whether soluble factors derived from granulocytes, such as matrix metalloproteinase 9 (MMP-9), myeloperoxidase (MPO), and arginase 1 (ARG1), and inhibitory cytokine TGFβ in pre-vaccination plasma were useful for predicting prognosis after PPV in advanced cancer patients. In biliary tract cancer (n=25), multivariate Cox regression analysis demonstrated that patients with higher plasma MMP-9 levels had a significantly worse overall survival (OS) [hazard ratio (HR) = 4.637, 95% confidence interval (CI) = 1.670 - 12.877, P = 0.003], whereas MPO, ARG1, or TGFβ levels were not correlated with OS. Similarly, patients with higher MMP-9 levels showed worse prognosis than those with lower MMP-9 levels in other types of advanced cancers, including non-small cell lung cancer (n=32, P = 0.037 by log-rank test), and pancreatic cancer (n=41, P = 0.042 by log-rank test). Taken together, plasma MMP-9 levels before vaccination might be potentially useful as a biomarker for selecting advanced cancer patients who would benefit from PPV., This study was supported by a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of Education, Culture, Sports, Science and Technology of Japan; a research program of the Regional Innovation Cluster Program of the Ministry of Education, Culture, Sports, Science and Technology of Japan; and Kurozumi Medical Foundation.

Published
2015

35. Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele

Author

Sakamoto, Shinjiro, Matsueda, Satoko, Takamori, Shinzo, Toh, Uhi, Noguchi, Masanori, Yutani, Shigeru, Yamada, Akira, Shichijo, Shigeki, Yamada, Teppei, Suekane, Shigetaka, Kawano, Kouichiro, Sasada, Tetsuro, Hattori, Noboru, Kohno, Nobuoki, Itoh, Kyogo, Sakamoto, Shinjiro, Matsueda, Satoko, Takamori, Shinzo, Toh, Uhi, Noguchi, Masanori, Yutani, Shigeru, Yamada, Akira, Shichijo, Shigeki, Yamada, Teppei, Suekane, Shigetaka, Kawano, Kouichiro, Sasada, Tetsuro, Hattori, Noboru, Kohno, Nobuoki, and Itoh, Kyogo

Abstract

type:text, To develop a peptide vaccine for cancer patients with the HLA-A26 allele, which is a minor population worldwide, we investigated the immunological responses of HLA-A26+ ⁄ A26+ cancer patients to four different CTL epitope peptides under personalized peptide vaccine regimens. In personalized peptide vaccine regimens, two to four peptides showing positive peptide-specific IgG responses in pre-vaccination plasma were selected from the four peptide candidates applicable for HLA-A26+ ⁄ A26+ cancer patients and administered s.c. Peptide-specific CTL and IgG responses along with cytokine levels were measured before and after vaccination. Cell surface markers in PBMCs and plasma cytokine levels were also measured. In this study, 21 advanced cancer patients, including seven lung, three breast, two pancreas, and two colon cancer patients, were enrolled. Their HLAA26 genotypes were HLA-A26:01 (n = 24), HLA-A26:03 (n = 10), and HLA-A26:02 (n = 8). One, 14, and 6 patients received two, three, and four peptides, respectively. Grade 1 or 2 skin reactions at the injection sites were observed in the majority of patients, but no severe adverse events related to the vaccination were observed. Peptide-specific CTL responses were augmented in 39% or 22% of patients after one or two cycles of vaccination, respectively. Notably, peptide-specific IgG were augmented in 63% or 100% of patients after one or two cycles of vaccination, respectively. Personalized peptide vaccines with these four CTL epitope peptides could be feasible for HLA-A26+ advanced cancer patients because of their safety and higher rates of immunological responses., This study was supported in part by the Japan Agency for Medical Research and development, AMED, a research program of the Regional Innovation Cluster Program of the Ministry of Education, Culture, Sports, Science and Technology of Japan, and a grant from the Sendai Kousei Hospital.

Published
2015

36. Immunological evaluation of peptide vaccination for cancer patients with the HLA‐A26 allele

Author

Sakamoto, Shinjiro, primary, Matsueda, Satoko, additional, Takamori, Shinzo, additional, Toh, Uhi, additional, Noguchi, Masanori, additional, Yutani, Shigeru, additional, Yamada, Akira, additional, Shichijo, Shigeki, additional, Yamada, Teppei, additional, Suekane, Shigetaka, additional, Kawano, Kouichiro, additional, Sasada, Tetsuro, additional, Hattori, Noboru, additional, Kohno, Nobuoki, additional, and Itoh, Kyogo, additional

Published
2015
Full Text
View/download PDF

37. Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination

Author

Sakamoto, Shinjiro, primary, Yoshitomi, Munehiro, additional, Yutani, Shigeru, additional, Terazaki, Yasuhiro, additional, Yoshiyama, Koichi, additional, Ioji, Tetsuya, additional, Matsueda, Satoko, additional, Yamada, Akira, additional, Takamori, Shinzo, additional, Itoh, Kyogo, additional, Hattori, Noboru, additional, Kohno, Nobuoki, additional, and Sasada, Tetsuro, additional

Published
2015
Full Text
View/download PDF

38. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients

Author

Yutani, Shigeru, primary, Ueshima, Kazuomi, additional, Abe, Kazumichi, additional, Ishiguro, Atsushi, additional, Eguchi, Junichi, additional, Matsueda, Satoko, additional, Komatsu, Nobukazu, additional, Shichijo, Shigeki, additional, Yamada, Akira, additional, Itoh, Kyogo, additional, Sasada, Tetsuro, additional, Kudo, Masatoshi, additional, and Noguchi, Masanori, additional

Published
2015
Full Text
View/download PDF

39. Phase II Study of Personalized Peptide Vaccination for Previously Treated Advanced Colorectal Cancer

Author

Kibe, Shiro, primary, Yutani, Shigeru, additional, Motoyama, Satoru, additional, Nomura, Takanobu, additional, Tanaka, Natsuki, additional, Kawahara, Akihiko, additional, Yamaguchi, Tomohiko, additional, Matsueda, Satoko, additional, Komatsu, Nobukazu, additional, Miura, Masatomo, additional, Hinai, Yudai, additional, Hattori, Satoshi, additional, Yamada, Akira, additional, Kage, Masayoshi, additional, Itoh, Kyogo, additional, Akagi, Yoshito, additional, and Sasada, Tetsuro, additional

Published
2014
Full Text
View/download PDF

40. Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ allele.

Author

Sakamoto, Shinjiro, Matsueda, Satoko, Takamori, Shinzo, Toh, Uhi, Noguchi, Masanori, Yutani, Shigeru, Yamada, Akira, Shichijo, Shigeki, Yamada, Teppei, Suekane, Shigetaka, Kawano, Kouichiro, Naitou, Masayasu, Sasada, Tetsuro, Hattori, Noboru, Kohno, Nobuoki, and Itoh, Kyogo

Abstract

The HLA-A11 or -A33 allele is found in approximately 18% or 10% of the Asian population, respectively, but each of which is a minor allele worldwide, and therefore no clinical trials were previously conducted. To develop a therapeutic peptide vaccine for each of them, we investigated immunological responses of advanced cancer patients with the HLA-A11+/A11+ ( n = 18) or -A33+/A33+ ( n = 13) allele to personalized peptide vaccine ( PPV) regimens. The primary sites of HLA-A11+/A11+ or -A33+/A33+ patients were the colon ( n = 4 or 2), stomach (2 or 3), breast (3 or 2), lung and pancreas (2 or 2), and so on. For PPV, a maximum of four peptides were selected from nine different peptides capable of binding to HLA-A11 and -A33 molecules based on the pre-existing peptide-specific IgG responses. There were no severe adverse events related to PPV. At the end of the first cycle, peptide-specific CTL responses were augmented in 4/12 or 2/9 of HLA-A11+/A11+ or -A33+/A33+ patients, while peptide-specific IgG responses were augmented in 6/14 or 4/10 patients, respectively. Clinical responses consisted of four stable diseases and 14 progressive diseases in HLA-A11+/A11+patients, versus seven and six in -A33+/A33+patients, respectively. Further clinical study of PPV could be recommended because of the safety and positive immunological responses. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

46. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis

Author

YOSHITOMI, MUNEHIRO, primary, YUTANI, SHIGERU, additional, MATSUEDA, SATOKO, additional, IOJI, TETSUYA, additional, KOMATSU, NOBUKAZU, additional, SHICHIJO, SHIGEKI, additional, YAMADA, AKIRA, additional, ITOH, KYOGO, additional, SASADA, TETSURO, additional, and KINOSHITA, HISAFUMI, additional

Published
2011
Full Text
View/download PDF

47. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination

Author

Noguchi, Masanori, primary, Mine, Takashi, additional, Komatsu, Nobukazu, additional, Suekane, Shigetaka, additional, Moriya, Fukuko, additional, Matsuoka, Kei, additional, Yutani, Shigeru, additional, Shichijo, Shigeki, additional, Yamada, Akira, additional, Toh, Uhi, additional, Kawano, Kouichiro, additional, Azuma, Kouichi, additional, Uemura, Hirotsugu, additional, Okuno, Kiyotaka, additional, Matsumoto, Kazumasa, additional, Yanagimoto, Hiroaki, additional, Yamanaka, Ryuya, additional, Oka, Masaaki, additional, Todo, Satoru, additional, Sasada, Tetsuro, additional, and Itoh, Kyogo, additional

Published
2010
Full Text
View/download PDF

48. Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer

Author

YAMADA, AKIRA, primary, NOGUCHI, MASANORI, additional, KOMATSU, NOBUKAZU, additional, SUEKANE, SHIGETAKA, additional, YUTANI, SHIGERU, additional, MORIYA, FUKUKO, additional, MINE, TAKASHI, additional, MOMOZONO, KOSUKE, additional, KAWANO, KOICHIRO, additional, and ITOH, KYOGO, additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results